NextCell yesterday announced six-year follow-up data for ProTrans in type 1 diabetes, confirming that approximately 50% of endogenous insulin production is preserved six years post-treatment. The shares are up 20% since the announcement, reflecting increased confidence in investment case ahead of the important readout of ProTrans-Young in Q3 this year.
LÄS MER
